All News
Filter News
Found 189 articles
-
Anders Vadsholt takes over as CEO of Orphazyme
2/28/2022
Orphazyme A/S, a late-stage biopharmaceutical company, announces that CFO Anders Vadsholt will be appointed CEO of Orphazyme effective as of March 1, 2022 and thereby replacing Christophe Bourdon as announced in company announcement no. 3/2022 of January 31, 2022.
-
The agreement would have created a spin-off gene therapy company and merged it with ARYA IV to create a new, publicly-traded entity called Caritas Therapies.
-
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
2/24/2022
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), today commented on Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC") by the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA").
-
Orphazyme announces update on regulatory review of arimoclomol in the European Union
2/23/2022
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
-
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
2/18/2022
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, announces that the Company has issued new shares in the period from Friday, February 11, 2022 to Thursday, February 17, 2022 as a result of the utilization of the Company’s U.S. At-the-Market Offering Program with Cowen and Company, LLC (“Cowen”).
-
Resolutions passed at the Extraordinary General Meeting - Feb 15, 2022
2/15/2022
Orphazyme A/S, a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, held an Extraordinary General Meeting, at which the general meeting:
-
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
2/14/2022
CytRx Corporation today highlighted Orphazyme A/S for the treatment of Niemann-Pick disease type C ("NPC"). CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.
-
CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO
2/8/2022
Centogene N.V. today announced plans for the transition of Chief Financial Officer René Just and the appointment of Miguel Coego Rios as Executive Vice President of Finance & Legal and Interim CFO. René Just has resigned from the Company effective March 31, 2022.
-
This week, two biotechnology firms announced new leadership, David Nassif, J.D., and Christophe Bourdon.
-
CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer
2/1/2022
Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the Company’s Supervisory Board’s nomination of Kim Stratton as Chief Executive Officer, transitioning from her prior designation as Interim CEO.
-
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
1/31/2022
Orphazyme A/S Company today announces that Chief Executive Officer (CEO) Christophe Bourdon will resign from his position as CEO at Orphazyme.
-
Notice to convene Extraordinary General Meeting
1/24/2022
Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that an Extraordinary General Meeting of the Company will be held on: Tuesday, February 15, 2022at 5:00 PM (CET).
-
Orphazyme updates 2021 financial outlook
1/18/2022
Orphazyme A/S today announces an update to its financial outlook for 2021 based on a review of preliminary unaudited financial results for the year ending December 31, 2021.
-
CytRx to Hold Town Hall for Stockholders on Thursday, January 20th
1/18/2022
CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern.
-
Acid Sphingomyelinase Deficiency Market is driven by increase in genetic mutations
1/18/2022
Acid sphingomyelinase is one of the enzymes from the family sphingomyelinase. It is an enzyme responsible for the development of phosphorylcholine and ceramide molecules through the breakdown of sphingomyelin.
-
CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference
1/7/2022
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that John Caloz, the Company’s Chief Financial Officer, is scheduled to present at the H.C. Wainwright BioConnect Virtual Conference.
-
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer
1/3/2022
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022.
-
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer
12/21/2021
CytRx Corporation today highlighted ImmunityBio, Inc.'s (NASDAQ: IBRX) ("ImmunityBio") recent clinical developments in the study of aldoxorubicin to treat various cancers.
-
NeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical Officer to Leadership Team
12/21/2021
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the appointment of four new directors upon the closing of the company's recent IPO.
-
CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO
12/20/2021
Centogene N.V. announced that its Chief Executive Officer, Andrin Oswald, M.D., is taking a temporary medical leave of absence for a period of at least four weeks.